Philadelphia, PA, January 12, 2019 --(PR.com
)-- Bioquark, Inc. an innovative life sciences company focused biotherapeutic development for human regeneration and disease reversion, and Ectocrine Technologies LLC, a biotech company dedicated to studying the positive human physiological effects of salivary secretions of hematophagous arthropods, such as mosquitos, of have announced a collaboration to focus on developing novel bio-products for human health and wellness.
"We are very excited about this collaboration with Ectocrine Technologies," said Ira S. Pastor, CEO, Bioquark Inc. "The synergy of our approaches in studying evolutionarily perfected arrays of metabolites from the natural world, can lead to the development of novel therapeutics for a range of chronic diseases responsible for human degeneration and suffering. And nature’s ectocrine systems (the 'Ectocrinome') represents a completely un-tapped reservoir."
Nature’s ectocrine systems (or “Ectocrinome,” in similar model to the Microbiome), form an interlaced network across species, providing a range of beneficial bio-active effects. The saliva of mosquitos, as example, has been shown to contain novel neuro-peptides, anti-inflammatory molecules, anti-coagulants, pain killers, as well as a range of vasodilatory and immune-modulatory molecules. However, most of this knowledge has been completely obscured due to the extensive popular press focus on the mosquito being no more than a disease carrying pest.
Mosquito eradication programs, while offering a solution to the million deaths each year from mosquito born disease, ignore the critical immunopathological role that these creatures have played over hundreds of millions of years as they propagated their beneficial biochemical signals in invertebrates, fish, amphibians, reptiles, birds, mammals, and humans. While hygiene represents one of the most successful health / life extending interventions in history, many epidemiological studies show that, paradoxically, it may render humans at risk for the development of a range of chronic non-communicable diseases (NCDs), such as inflammatory bowel disease, multiple sclerosis, type I diabetes, asthma, and allergies. Furthermore, these pathological process might play a broad role in the pathogenesis of other NCDs associated with chronic inflammation such as atherosclerosis, type 2 diabetes, cancer, and neurodegenerative disorders.
"We look forward to working closely with Bioquark Inc. on this exciting initiative," said Dr. J. Santiago Mejia MD, CSO of Ectocrine Technologies LLC. "The epidemiological evidence of low incidences of auto-immune diseases, inflammatory disorders, allergies, developmental diseases and certain cancers, in regions of high endemicity for arthropod-borne diseases, may interestingly point us towards previously ignored answers to combat these major causes of human degeneration and disease."
“We are not advocating for the suspension of the vector control programs used to eradicate malaria and other arthropod-borne diseases. Our concern is that these methods fail to discriminate infected from non-infected mosquitos, and as a result, residents of intervened areas are deprived of the potential health benefits derived from exposure to the salivary molecules delivered through the bite of healthy mosquitos,” said Mejia.
About Bioquark, Inc.
Bioquark, Inc. is an innovative life sciences company focused on the development of novel bio-products for human regeneration, disease reversion and rejuvenation, in relation to aging and age related pathologies.
About Ectocrine Technologies
Ectocrine Technologies LLC is a biotech company dedicated to studying the positive human physiological effects of salivary secretions of hematophagous arthropods, such as mosquitos, as an essential source of molecules for human well-being and development.